Summary:
The purpose of this study is to determine if treatment with dempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in patients who are statin intolerant
Qualified Participants Must:
• Age between 18 and 85 years
• History of, or at high risk for, cardiovascular disease (CVD) including coronary artery disease, symptomatic peripheral arterial disease, cerebrovascular atherosclerotic disease, or at high risk for a cardiovascular event
•Patient reported history of statin intolerance
• Men and nonpregnant, nolactating women
• Fasting blood LDL-cholesterol greater than 100 at screening
Qualified Participants May Receive:
Compensation for time and travel